CSL Enters Into An Exclusive Licensing Agreement With Eli Lilly, Granting Certain Rights To Develop And Commercialize Clazakizumab For An Upfront Payment Of $100M And Potential Milestone Payments, As Well As Sales-based Royalties

+0.72%

-1.02%

Eli Lilly and Company

LLY

990.33

+0.72%

CSL LTD

CSLLY

25.15

-1.02%

Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with end-stage kidney disease (ESKD).
CSL is advancing the ongoing POSIBIL 6ESKD Phase 3 clinical trial (NCT05485961), which is evaluating the efficacy and safety of clazakizumab in patients with ESKD on dialysis at risk for major cardiovascular events.
Under the terms of the agreement, CSL will retain exclusive rights to develop and commercialise clazakizumab for the prevention of cardiovascular events in patients with ESKD.
Lilly will explore the development, global regulatory approval, and commercialisation of clazakizumab in additional indications. CSL will receive an upfront payment of $100 million and be eligible to receive potential clinical, regulatory and commercial milestone payments, as well as royalties on global net sales

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.